M. Keith et al., INCREASED OXIDATIVE STRESS IN PATIENTS WITH CONGESTIVE-HEART-FAILURE, Journal of the American College of Cardiology, 31(6), 1998, pp. 1352-1356
Objectives. We sought to study the markers of lipid peroxidation and d
efenses against oxidative stress in patients with varying degrees of h
eart failure. Background. Despite advances in other areas of cardiovas
cular disease, the morbidity and mortality from congestive heart failu
re (CHF) are increasing, Data mainly from animal models suggest that f
ree radical injury may promote myocardial decompensation. However, the
re are no studies in humans correlating the severity of heart failure
with increased free radical injury and antioxidants. Methods. Fifty-ei
ght patients with CHF and 19 control subjects were studied. In additio
n to complete clinical and echocardiographic evaluations, the prognosi
s of these patients was established by measuring the levels of soluble
tumor necrosis factor-alpha receptors 1 and 2 (sTNF-R1 and sTNF-R2).
Oxidative stress was evaluated by measuring plasma lipid peroxides (LP
O), malondialdehyde (MDA), glutathione peroxidase (GSHPx) and vitamin
E and C levels. Results. The patients' age range, cause of heart failu
re and drug intake were comparable across the different classes of hea
rt failure. Heart failure resulted in a significant increase in LPO (p
< 0.005), MDA (p < 0.005), sTNF-R1 (p < 0.005) and sTNF-R2 (p < 0.005
). There was a significant positive correlation between the clinical c
lass of heart failure and LPO, MDA, sTNF-R1 and sTNF-R2 levels, There
was an inverse correlation between GSHPx and LPO, With increased lipid
peroxidation in patients with CHF, the levels of vitamin C decreased,
but vitamin E levels were maintained. Conclusions. These data demonst
rate a progressive increase in free radical injury and encroachment on
antioxidant reserves with the evolution of heart failure; they also s
uggest that oxidative stress may be an important determinant of progno
sis, The therapeutic benefit of administering antioxidant supplements
to patients with CHP should be evaluated. (C) 1998 by the American Col
lege of Cardiology.